SOMAmer® Specificity


SomaLogic commitment to providing accurate information on the reliability and specificity of SOMAmer protein-affinity reagents in the SomaScan® Assay

The key to reliable protein measurement using affinity reagents of any kind is the continuous evaluation of the specificity of those reagents for their target protein. Cross-reactivity and protein target preparation artifacts are both known issues that can compromise the utility of any given reagent. For example, it is estimated that approximately 50% of commercially available antibodies are either incorrect, insufficiently specific for their putative target protein or inadequate for the use being considered (Berglund 2008).

It is critical that protein measurements for both basic research and clinical uses are accurate and reproducible. Leveraging years of experience, SomaLogic has implemented several methods that allow us to regularly evaluate both existing and new SOMAmer reagents. To date, our quality-commitment efforts have helped us keep the number of reagents with uncertain target-binding profiles at very low levels in the SomaScan Assay. These efforts have helped us refine and further improve each subsequent version of the assay.

In addition to replacing SOMAmer reagents we uncover as suboptimal, SomaLogic is committed to transparency by regularly communicating that information to past, present and potential users and collaborators. We undertake these efforts because we understand that results from SomaScan studies must be obtained with the highest quality control so that data can be properly analyzed and interpreted.

For more information on how we validate specificity of SOMAmer reagents in the SomaScan Assay please download our “Short Technical Note”. You should also contact us with any further questions or comments, or to request the most recent version of the SomaScan Assay annotated menu.


Berglund L et al. (2008) “A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies.” Molecular and Cellular Proteomics 7(10) 2019-2027.